# Advanced Biliary Tract Cancer: Exploration of Third-Line and Other Therapeutic Areas After Failure of Chemotherapy Alone

## TL;DR

This review explores treatment options for advanced biliary tract cancer after chemotherapy fails, aiming to improve patient outcomes with new strategies.

## Contribution

The paper provides a comprehensive review of third-line and other therapeutic approaches for biliary tract cancer after chemotherapy failure.

## Key findings

- Most biliary tract cancer patients are diagnosed at an unresectable stage, making systemic therapy critical.
- Third-line treatment may extend survival but faces challenges like poor tolerance and drug toxicity.
- Combining chemotherapy, targeted therapy, immunotherapy, and radiotherapy could form a standardized third-line strategy.

## Abstract

The diagnosis and treatment of advanced biliary tract cancer face numerous challenges, including the lack of highly specific diagnostic methods, insufficient healthcare system support, and the absence of standardized and effective treatment options after the failure of multiple lines of therapy. This review aims to improve the prognosis of biliary tract cancer by presenting standard treatment regimens, clinical trials, and experimental findings, thereby providing new insights for subsequent-line therapy in advanced disease.

Biliary tract cancer (BTC) is a highly aggressive malignancy with an extremely poor prognosis and a gradually increasing incidence, warranting increased clinical attention. The majority of BTC patients are diagnosed at an unresectable stage, making systemic therapy—including first-line and subsequent treatments—critical for outcomes. However, due to disparities in medical resources and limited understanding of the disease, outcomes following first- and second-line therapies remain suboptimal. In this context, third-line treatment offers a potential opportunity to further extend patient survival, although challenges such as poor treatment tolerance and significant drug-related toxicities remain. A rational integration of chemotherapy, targeted therapy, immunotherapy, and novel radiotherapy techniques may constitute a standardized third-line therapeutic strategy for BTC. This review aims to discuss potential therapeutic adaptations and options in the setting where conventional chemotherapy has failed.